Product Code: GVR-1-68038-010-1
Critical Care Diagnostics Market Growth & Trends:
The global critical care diagnostics market size is expected to reach USD 1.72 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The key factors supporting the industry's growth comprise the rapid awareness and acknowledgment of these tests by physicians and patients, the rise in geriatric population and chronic health conditions, the employment of telehealth services in remote areas, and technological advancements. The increased cost of the molecular diagnostics and dearth of skilled labor are factors that are expected to hinder the growth of the industry.
The critical care diagnostics market by type is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation testing, and others. The microbial and infectious diseases test diagnostics segment is projected to grow at the highest rate with a CAGR of over 5.5% during the forecast period. For example, healthcare systems spend a substantial amount of resources in the collection and processing of blood cultures for the identification of pathogens.
Critical care diagnostic tests, such as the nucleic acid amplification test, allow clinicians to detect and identify organisms more rapidly and accurately and provide guidance to clinicians, who aspire to commence the appropriate antimicrobial therapy as fast as possible and terminate the use of avoidable drugs. The critical care diagnostic market by the end-user is categorized into operation rooms, emergency rooms, and ICU's. The emergency rooms segment in the industry is anticipated to witness the highest growth rate during the forecast period.
Critical Care Diagnostics Market Report Highlights:
- The Asia Pacific region is expected to grow at the fastest CAGR of 6.9% during the forecast period. The large presence of geriatric population, increasing prevalence of chronic diseases, increase in the number of specialty hospitals in the Asia Pacific region, and improving healthcare services and infrastructures in rural areas are the factors fueling the market growth.
- The immunoproteins diagnostic test segment is estimated to account for the largest share of the critical care diagnostic market by type. The rise in demand for rapid and accurate preventive healthcare services is one of the major factors driving this market growth.
- On the basis of end-users, approximately 20% of acute-care patients get admitted into ICU's, whereas nearly 58% get admitted into emergency rooms. The emergency rooms are expected to witness exponential growth with the highest CAGR during the forecast period. The recent rise in the patient demand for ER services is due to its ability to provide initial acute care diagnosis and treatment of critically ill patients.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. End Use
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. End use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Critical Care Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Critical Care Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Critical Care Diagnostics: Type Estimates & Trend Analysis
- 4.1. Critical Care Diagnostics Market: Key Takeaways
- 4.2. Critical Care Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Routine and Special Chemistry
- 4.3.1. Routine and special chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Flow Cytometry
- 4.4.1. Flow cytometry market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Hematology
- 4.5.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Immunoproteins
- 4.6.1. Immunoproteins market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.7. Microbial and Infectious Disease
- 4.7.1. Microbial and infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.8. Coagulation Testing
- 4.8.1. Coagulation testing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.9. Others
- 4.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Critical Care Diagnostics: End Use Estimates & Trend Analysis
- 5.1. Critical Care Diagnostics Market: Key Takeaways
- 5.2. Critical Care Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Operation Room
- 5.3.1. Operation room market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Intensive Care Unit
- 5.4.1. Intensive care unit market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Emergency Rooms
- 5.5.1. Emergency rooms market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Critical Care Diagnostics Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Critical Care Diagnostics Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. Abbott
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Danaher
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. F. Hoffmann-La Roche Ltd
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. BD
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. EKF Diagnostics
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. bioMerieux, Inc.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Siemens Healthcare Private Limited
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Chembio Diagnostics, Inc.
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. Bayer AG
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives